Pleural
Adverse Renal Outcomes in Patients With Mesothelioma-A Territory-Wide Real-World Data
Cancer Medicine 2026 February [Link] Wang Chun Kwok, James Chung Man Ho, Isaac Sze Him Leung, Desmond Yat Hin Yap Abstract Introduction: Advances in mesothelioma management have translated into longer patient survival and different treatment-related side effects including nephrotoxicity. The risk of developing adverse renal outcomes in patients with mesothelioma and associated risk factors remains…
Read MoreClinical applications of cryobiopsy in the diagnosis of thoracic malignancies: a comprehensive review
Japanese Journal of Clinical Oncology 2026 January 30 [Link] Miwa Kamatani, Nobuyasu Awano, Takehiro Izumo Abstract Accurate histopathological and molecular characterization of lung cancer is essential for optimal treatment selection in the era of precision medicine. While conventional biopsy techniques are widely available and safe, they often yield small tissue samples with crush artifacts that…
Read MoreTreatment Patterns, Clinical Outcomes, Health Care Resource Use, and Costs in Older Adults with Malignant Pleural Mesothelioma in the United States, 2007-2020
Advances in Therapy 2026 March [Link] Himani Aggarwal, Ashwini Arunachalam, Jae Min, Yu-Han Kao, Haidong Feng, Danmeng Huang, Gloria Odonkor Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare malignancy typically attributed to occupational asbestos exposure and associated with dismal survival outcomes. The standard of care for unresectable MPM was platinum-based chemotherapy until the approval…
Read MorePembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical Trial
Clinical Lung Cancer 2026 March [Link] Tetsuya Takagawa, Kanae Takahashi, Yuji Orimoto, Yukie Morisaki, Shinichiro Suna, Takashi Daimon, Takashi Kijima, Kozo Kuribayashi Abstract Background: In pleural mesothelioma (PM), platinum-based chemotherapy and immune checkpoint inhibitors including nivolumab and ipilimumab have been approved but have not shown sufficient therapeutic efficacy, and the development of new therapies is…
Read MoreMechanisms of Chemoresistance in Malignant Pleural Mesothelioma: The Regulatory Role of miRNAs
Archives of Medical Research 2026 January 27 [Link] Andrea Martinez-Marroquin, Javier Gaytán-Cervantes, Haydeé Rosas-Vargas, Constantino López-Macías, Itzel Peralta-Salguero, Miguel Cid-Soto, Violeta Castro Leyva, Marlon De Ita, Carolina González-Torres Abstract Malignant pleural mesothelioma (MPM), is a rare and aggressive cancer that originates in the mesothelium lining the lungs. It is considered an occupational disease associated with…
Read MoreEvaluation of respiratory toxicity and peritoneal mesothelioma induced by heat-treated and milled amosite following intratracheal and intraperitoneal injection in rats
Industrial Health 2026 January 29 [Link] Hiroshi Yamauchi, Ayako Takata, Kiyotsugu Yamashita, Masahito Aminaka, Toshiaki Hitomi, Norihiko Kohyama Abstract Amoste is highly carcinogenic, and its incomplete removal from the environment continues to pose significant health risks. High temperatures are known to alter the crystal structure of asbestos. In this study, we evaluated the carcinogenicity and…
Read MoreTime to next procedure in patients with malignant pleural effusion undergoing aspiration: derivation and initial validation of the RED score
Thorax 2026 January 28 [Link] Eleanor K Mishra, Helen Davies, Syed Hamza Abbas, Cheryl Hardy, Dominic T Beith, Dheeraj Sethi, Toshit Sapkal, Alguili Elsheikh, Asfandyar Yousuf, Emma L Hedley, Ellie Daly, Anand Sundaralingam, Dinesh Addala, Samantha A Jones, Lianne Castle, Neena Patel, Jurgen Herre, Hannah Collins, Jack Kastelik, Clare L Ross, John Corcoran, Cyrus Daneshvar,…
Read MoreReactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma
Antioxidants 2026 January 17 [Link] Muhammad Hashim, Gerald Timelthaler, Dominik Kirchhofer, Beatrice Irina Kudlacek, Berta Mosleh, Katharina Sinn, Ezzat Mohamed Awad, Mir Alireza Hoda, Bettina Grasl-Kraupp, Balazs Dome, Walter Berger, Georg Krupitza, Karin Schelch, Michael Grusch Abstract Reactive oxygen species (ROS)-induced aberrant oncogenic signalling has been proposed to mediate the progression and development of pleural…
Read MorePD-L1 and BAP1 as Prognostic Biomarkers in Malignant Pleural Mesothelioma
Cells 2026 January 19 [Link] Milija Gajić, Vesna Ćeriman Krstić, Natalija Samardžić, Ivan Soldatović, Sofija Glumac, Milena Jovanović 4, Milan Savić, Mihailo Stjepanović, Spasoje Popević, Ruža Stević, Nikola Čolić, Katarina Lukić, Vladimir Milenković, Ivan Milivojević, Ivana Sekulović Radovanović, Dragana Jovanović Abstract Malignant pleural mesothelioma (MPM) is a very aggressive tumor. The prognostic value of PD-L1…
Read MorePrognostic value and clinical significance of tumoral PD-L1 and stromal α-SMA expression in diffuse pleural mesothelioma
Neoplasma 2026 February [Link] Yeqi Sun, Lan Li, Lei Cai, Jihua Yang, Jun Qian, Fajiu Wang, Lifeng Wang Abstract Diffuse pleural mesothelioma (PM) is a rare malignant neoplasm with an extremely poor prognosis. Prognostic assessment remains challenging, highlighting the urgent need for reliable biomarkers to guide precise and effective therapy. Programmed death ligand 1 (PD-L1)…
Read More
Skip to content